Objective: To observe the efficacy and safety of multi-target (tacrolimus+ mycophenolate
mofetil+ prednisone) therapy for type III+ V and IV+ V type lupus nephritis. Methods: A total of …

The aim of this study was to explore whether progranulin (PGRN) can be a useful marker not
only for accurate diagnosis of patients with active lupus nephritis (LN), but also for prediction …

Lupus nephritis (LN) is a common and severe manifestation of systemic lupus
erythematosus (SLE). LN is a glomerulonephritis characterized by the accumulation of …

Objectives We previously revealed the role of prolactin (PRL) in antibody production and
disease activity in patients with systemic lupus erythematosus. In this study, we sought to …

Background: Mycophenolate (MF) is effective as a maintenance therapy after induction
therapy in patients with lupus nephritis (LN). However, little is known about its role in …

Lupus nephritis (LN) is the leading cause of mortality in lupus patients. This study aimed to
investigate the treatment outcome and renal histological risk factors of LN in a tertiary …

Involvement of the kidneys by lupus nephritis (LN) is one of the most severe clinical
manifestations seen in individuals with systemic lupus erythematosus (SLE). LN is more …

In recent trials for the treatment of systemic lupus erythematosus (SLE), belimumab (BLM), in
addition to standard immunosuppression, has been shown to improve renal and nonrenal …

Lupus nephritis (LN) occurs in~ 50% of patients with systemic lupus erythematosus and is a
major cause of morbidity and mortality of the affected individuals. Therefore, identification of …

Background: Monthly intravenous cyclophosphamide (IVCY) is a widely accepted induction
therapy for lupus nephritis (LN) because this regimen balances the time needed for renal …